Genetic association between plasminogen activator inhibitor‐1 rs1799889 polymorphism and venous thromboembolism: Evidence from a comprehensive meta‐analysis

Abstract

BackgroundAssociation between plasminogen activator inhibitor‐1 (PAI‐1) rs1799889 polymorphism and venous thromboembolism (VTE) were explored by many previous studies, yet the findings of these studies were conflicting.Hypothesis PAI‐1 rs1799889 polymorphism may serve as a genetic marker of VTE. We aimed to better clarify the relationship between PAI‐1 rs1799889 polymorphism and VTE in a larger combined population by performing a meta‐analysis.MethodsLiteratures were searched in Pubmed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI). We used Review Manager to combine the results of individual studies.ResultsForty‐eight studies involving 14 806 participants were eligible for inclusion. Combined results revealed that PAI‐1 rs1799889 polymorphism was significantly associated with VTE in Caucasians (dominant comparison: odds ratio [OR] 1.20, 95% confidence interval [CI] 1.09‐1.32; recessive comparison: OR 0.84, 95% CI 0.76‐0.94; allele comparison: OR 1.08, 95% CI 1.02‐1.15) and East Asians (dominant comparison: OR 1.60, 95% CI 1.17‐2.19; allele comparison: OR 1.53, 95% CI 1.21‐1.93). Further analyses obtained similar significant associations in these with deep vein thrombosis (DVT) and these with Factor V Leiden mutation.ConclusionsOur findings supported that PAI‐1 rs1799889 polymorphism may serve as one of the predisposing factors of VTE in both Caucasians and East Asians, especially in these with DVT and these with Factor V Leiden mutation.

Methylenetetrahydrofolate reductase (MTHFR) gene c.655C>T and c.1286A>C and SERPINE 1 -675 4G/5G polymorphisms in Polish patients with venous thromboembolism and cryptogenic ischemic stroke

“…The SERPINE1 -675 4G/5G minor allele frequencies detected in our study (0.53-0.56) are slightly higher than those reported in patients with VTE from Germany (0.44-0.49) and France (0.47) and similar to the values observed in the United Kingdom (0.53) [10]. To our knowledge, we are the first to show Polish data on these genetic variants in VTE patients.…”

Hypercoagulation detected by routine and global laboratory hemostasis assays in patients with infective endocarditis

“…Other coagulation system polumorphisms such as FXIII V34L polymorphism are less studied, but some studies show their potential for thrombosis risk evaluation [ 13 ]. As for the fibrinolysis PAI-1 polymorphism may serve as one of the predisposing factors of VTE [ 14 ]. Platelet glycoprotein polymorphisms such as) platelet GP Ia/IIa ITGA2 gene polymorphism (rs1126643), platelet GP IIb/IIIa ITGB3 gene polymorphism (rs5918), platelet GP Ib GP1BA gene polymorphism (rs6065), platelet GPVI GP6 gene polymorphism (rs1613662) were associated with myocardial infarction, coronary disease or VTE [ 12 , 15 ].…”

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences

“…PAI-1 rs1799889 4G/5G polymorphism (4G vs. 5G) has been associated with an increased risk of DVT, MI and ischemic stroke. 54) 55) 56) …”

“…The significant linkage of PAI-1 rs1799889 polymorphism (4G vs. 5G) to the risks of DVT, CAD and ischemic stroke was more prominent in the Asian population. 55) 56) Limited studies have also identified lower levels of circulating protein C and protein S, and endogenous anticoagulants in African Americans. 59) 60) …”